Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like Gilead to Unveil New SoCal Facility That Could House Up to 500 Employees August 15, 2017 FDA Rejects Johnson & Johnson's RA Drug Sirukumab, More Safety Data Needed September 24, 2017 Agile Therapeutics, Inc. Reports Fourth Quarter And Full Year 2016 Financial Results March 8, 2017